Clinical Trials · NCT00971659
Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
- Enrollment
- 48
- Start date
- Jan 2008
- Locations
- 1 site, Germany
- Primary endpoint
- the unadjusted 6-hour postprandial blood glucose excursion (AUCBG0-6h) following ingestion of a standardized breakfast